ESTRADIOL
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.7M | 158 | 3 |
| 2023 | $1.5M | 161 | 3 |
| 2022 | $5,000 | 2 | 0 |
| 2018 | $200,744 | 14 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.4M | 335 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy | Teva Pharmaceuticals USA, Inc. | $3.2M | 3 |
| A Multiple Site Study to Compare the Cumulative Skin Irritation and Sensitization Potential of a Test Product Transdermal System Compared to the Marketed Estradiol Transdermal System DS320116 | Amneal Pharmaceuticals LLC | $152,669 | 0 |
| Open-Label, Single-Application, Two-Treatment, Two-Period, Crossover Pivotal Adhesion Study of One Test Formulation of Estradiol Film, Extended Release Transdermal 0.1 mg24 hour Amneal Pharmaceuticals Compared to Minivelle estradiol transdermal system 0.1 mg 24 hour Noven Pharmaceuticals,Inc in Healthy Post-Menopausal Female Subjects 38115 | Amneal Pharmaceuticals LLC | $48,075 | 0 |
| Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy | Teva Pharmaceuticals USA, Inc. | $5,000 | 0 |
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $3.2M
- Amneal Pharmaceuticals LLC $200,744
Product Information
- Type Drug
- Total Payments $3.4M
- Total Doctors 3
- Transactions 335
About ESTRADIOL
ESTRADIOL is a drug associated with $3.4M in payments to 3 healthcare providers, recorded across 335 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2018 to 2024. In 2024, $1.7M was paid across 158 transactions to 3 doctors.
The most common payment nature for ESTRADIOL is "Unspecified" ($3.4M, 100.0% of total).
ESTRADIOL is associated with 4 research studies, including "A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy" ($3.2M).